Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BECONASE vs DECASPRAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
FDA-approved: Management of seasonal or perennial allergic rhinitis,Off-label: Nonallergic rhinitis, nasal polyps, adjunctive treatment for sinusitis
Inflammatory dermatoses (e.g., eczema, dermatitis),Allergic skin reactions,Psoriasis,Lichen planus,Discoid lupus erythematosus
1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
1.5-3 hours (terminal elimination half-life); no accumulation with once-daily dosing.
The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence.
Primarily hydrolyzed by esterases in the lung, liver, and plasma to its active metabolite beclomethasone-17-monopropionate (17-BMP). Further metabolism via CYP3A4 to inactive metabolites.
Dexamethasone is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Primarily hepatic metabolism; <10% excreted renally as unchanged drug; biliary/fecal excretion accounts for minimal elimination.
Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug.
87% bound to plasma proteins, primarily corticosteroid-binding globulin and albumin.
Approximately 77% bound to serum proteins, primarily albumin and corticosteroid-binding globulin (CBG).
0.5-1.5 L/kg; indicates extensive distribution into tissues.
Volume of distribution is approximately 0.8 L/kg (range 0.5-1.0 L/kg). This indicates moderate distribution into tissues, with higher penetration into CNS compared to other glucocorticoids.
Intranasal: <1% systemic absorption due to extensive first-pass metabolism and local administration.
Oral bioavailability is approximately 80-90%. Intramuscular bioavailability is nearly 100% due to complete absorption. Intranasal bioavailability is low (<1%) due to local administration, but systemic absorption can occur with high doses.
No adjustment required.
No adjustment required for any degree of renal impairment.
No adjustment required.
No adjustment required for Child-Pugh Class A or B. For Child-Pugh Class C, caution advised due to lack of data; monitor for systemic effects.
Children 6-11 years: 1 spray (42 mcg) per nostril twice daily; children ≥12 years: same as adult.
Children 2-11 years: 1-2 sprays (200-400 mcg) intranasally twice daily. Maximum 4 sprays per day.
No specific adjustment; use lowest effective dose.
Same as adult dosing. No specific dose reduction required; monitor for adrenal suppression in prolonged use.
None
None
Risk of suppression of hypothalamic-pituitary-adrenal (HPA) axis with prolonged use at higher than recommended doses,Possible development of localized Candida albicans infections of the nose and pharynx,Caution in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex,Use with caution in patients with recent nasal ulcers, nasal surgery, or nasal trauma until healing has occurred
Topical corticosteroids may cause systemic absorption, leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Systemic absorption is increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients. Avoid use on face, groin, or axillae unless directed. Use caution in patients with bacterial, fungal, or viral skin infections; may mask or worsen infection. Discontinue if irritation or sensitization occurs.
Hypersensitivity to beclomethasone dipropionate or any component of the formulation,Untreated localized nasal mucosal infections (e.g., herpes simplex)
Hypersensitivity to dexamethasone or any component of the formulation; untreated bacterial, fungal, or viral skin infections; tuberculous skin lesions; syphilitic skin infections; vaccinia or varicella; perioral dermatitis; rosacea; acne vulgaris; broken or abraded skin.
No specific food interactions reported. Beconase is administered intranasally and has negligible systemic absorption, so dietary restrictions are not required.
No known food interactions. Avoid excessive intake of potassium-rich foods if prolonged use on large areas to mitigate risk of hypokalemia.
Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major congenital malformations or adverse fetal outcomes. However, the potential for fetal harm cannot be completely ruled out. Trimester-specific risks: First trimester: No evidence of teratogenicity in animal studies at clinically relevant doses, but human data are limited. Second and third trimesters: No increased risk of fetal growth restriction or adrenal suppression reported, but high doses may theoretically affect fetal adrenal function.
FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and premature closure of ductus arteriosus with prolonged use.
Inhaled beclomethasone is not expected to be present in breast milk in significant amounts due to low systemic bioavailability. The M/P ratio is not available. Manufacturer advises caution, but risk to infant is low. Use while breastfeeding is considered acceptable if maternal benefit outweighs potential risk.
Limited data; small amounts of dexamethasone excreted into breast milk; M/P ratio approximately 0.3-0.5. Theoretical risk of adrenal suppression; avoid high doses or monitor infant for growth and adrenal function.
No dose adjustment is generally required for inhaled beclomethasone during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered clearance) are not clinically significant for inhaled corticosteroids due to minimal systemic absorption. However, ensure the lowest effective dose is used to maintain asthma control.
No standard dose adjustment; use lowest effective dose. Increased clearance in third trimester may require higher doses to achieve therapeutic effect; monitor clinical response and adjust accordingly.
Beconase (beclomethasone dipropionate) is an intranasal corticosteroid for allergic rhinitis. Onset of action is not immediate; regular use for several days to weeks is required for full effect. Priming the nasal spray with 6 sprays before first use is essential. Avoid spraying directly onto the nasal septum to prevent irritation and bleeding. For best results, administer after clearing nasal passages. Systemic absorption is minimal at recommended doses, but monitor for growth suppression in children with prolonged high-dose use.
Decaspray (dexamethasone topical aerosol) is a potent corticosteroid for dermatologic use. Avoid use on infected skin without concurrent anti-infective therapy. Limit application to small areas and use sparingly to minimize systemic absorption. Do not use on face, groin, or axillae due to risk of atrophy. Discontinue if irritation or sensitization occurs.
Use Beconase regularly as prescribed, not for immediate symptom relief.,Prime the spray with 6 test sprays before first use or if not used for 7 days.,Blow nose gently before dosing to clear nasal passages.,Tilt head forward, insert nozzle into nostril, and spray away from the septum.,Avoid spraying into eyes or on the nasal septum.,Do not exceed recommended dosage; side effects are rare but include nasal irritation or nosebleeds.,Inform your doctor if symptoms do not improve after 3 weeks.,If also using a decongestant spray, use the decongestant first, then wait 10-15 minutes before Beconase.
Apply a thin film only to affected skin areas as directed.,Do not cover the treated area with bandages unless instructed by your doctor.,Avoid contact with eyes, mouth, or open wounds.,Do not use on diaper rash or under diapers.,Wash hands after application unless treating hands.,Inform your doctor if condition worsens or does not improve after 2 weeks.,Do not use for other conditions without consulting a healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BECONASE vs DECASPRAY, answered by our medical review team.
BECONASE is a Nasal Corticosteroid that works by Beclomethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce arachidonic acid release, and decrease production of prostaglandins and leukotrienes, thereby suppressing nasal mucosal inflammation.. DECASPRAY is a Intranasal Corticosteroid that works by Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BECONASE and DECASPRAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BECONASE is: 1-2 sprays (42-84 mcg) per nostril twice daily; intranasal.. The standard adult dose of DECASPRAY is: 2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BECONASE and DECASPRAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BECONASE is classified as Category C. Beclomethasone dipropionate (BECONASE) is an inhaled corticosteroid. In pregnant women, available data from cohort studies and case series do not show an increased risk of major co. DECASPRAY is classified as Category C. FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.